ClinicalTrials.gg
CompletedNCT01839279TQTUpdated Mar 23, 2021Results posted

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial

A Phase 2 interventional study of Tizanidine and Placebo in Spasticity, sponsored by Acorda Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-23.

Sponsored by Acorda Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 165 studies in Muscle Spasticity with a site in United States — 34 open to participants now, 44 under way, none of them phase 3. Muscle Spasticity · United States.

Enrollment
26th of 130
136 · median 31
Started
2013
with 9 others
Phase 2
18 of 165
3 open now
Registered
60th of 165
by date
Lead sponsor
4 of 165
Acorda Therapeutics

Among the 165 studies in Muscle Spasticity with a site in United States, this one is the 26th largest by enrollment of the 130 interventional ones that give a count, is one of 10 that started in 2013, is one of 18 in phase 2, and was the 60th registered.

Muscle Spasticity

622 studies on the registry are indexed under Muscle Spasticity; 128 are open to participants now.

Browse Muscle Spasticity studies →

Open to participants now

34 of the 165 studies in Muscle Spasticity with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Muscle Spasticity studies recruiting now, 29 (33%) set no upper age limit and 47 (53%) stop at 75 or younger; 34 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Muscle Spasticity with a site in United States, or all of them as a file.
02

Study summary

This is a single-center, partial-blind, randomized, placebo-controlled, parallel design study with a nested crossover comparison to define the ECG effects of tizanidine compared to placebo and the positive control, moxifloxacin, in healthy men and women. The study will be conducted in a Phase 1 unit with sufficient facilities to house subjects as required by the protocol.

03

Conditions studied

  • Spasticity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women of should have a negative urine pregnancy test prior to Screening and Day -2 of the trial
  • All subjects of childbearing potential must practice a highly effective method of excluding oral contraceptives for the duration of the trial and up to 3 months after the last dose of product. Oral contraceptives are not allowed, based on the precaution listed in the Zanaflex package insert.
  • Have a (BMI) ranging between 19 and 30 kg/m2
  • Comprehend and be able to provide written
  • Be willing and able to comply with all trial requirements

Exclusion criteria

Exclusion Criteria:

  • Female who is either pregnant, breastfeeding or planning to become pregnant
  • History of or allergic reaction to tizanidine or moxifloxacin or any of the tablet components
  • Any condition possibly affecting drug absorption, metabolism or excretion including previous surgery for removal of parts of stomach, bowel, liver, gall bladder, or pancreas
  • History of Long Syndrome or a first-generation relative with this condition
  • Evidence or history of allergies except for untreated, asymptomatic, seasonal allergies at time of dosing, hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, renal, psychiatric, or neurological disease. Determination of clinical significance is to be made at the Investigator's discretion
  • History or presence of any malignant or benign neoplasm considered by the investigator to be clinically significant
  • History of drug or alcohol abuse or dependence within the last year
  • Have an active infectious disease
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Tizanidine

    Oral dose of 2 and 4 milligram (mg) tablets

    Drug: Tizanidine

  • Placebo comparator
    Placebo

    Placebo followed by a single dose 400 mg moxifloxacin tablets.

    Drug: Placebo · Drug: Moxifloxacin

  • Active comparator
    Moxifloxacin

    Single dose of 400 mg moxifloxacin followed by placebo.

    Drug: Placebo · Drug: Moxifloxacin

Interventions

06

What researchers measure

Primary outcomes

  1. The Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (ΔΔQTc) on Day 14.

    Change from baseline in Cardiac Repolarization (QTc Interval) at Day 14 (Tizanidine 24 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.

    Time frame: Baseline and Day 14

Secondary outcomes

  1. The Baseline-adjusted, Placebo-corrected (ΔΔQTc) on QTc Method Not Selected as Primary Endpoint.

    Change from baseline in Cardiac Repolarization (QTc Interval) at Day 5 (Tizanidine 8 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.

    Time frame: Baseline and Day 5

  2. Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling

    The relationship will be quantified using a linear mixed effects model with an intercept. Data from Day 5 and Day 14 were fitted into regression model to obtain a slope of change. The measure type 'Number' followed by (90% Confidence Interval) shown in results is the slope from the linear fit.

    Time frame: Day 5, Day 14

  3. Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.

    Time frame: 0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)

  4. Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.

    Time frame: 0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)

  5. Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.

    Time frame: 0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)

07

Results

Posted Jun 1, 2015

Participant flow

Participant flow — Overall Study
MilestoneTizanidineInitial Placebo and Crossover to MoxifloxacinInitial Moxifloxacin and Crossover to Placebo
Started723232
Qt/qtc analysis set723232
Pk analysis set7000
Moxifloxacin/placebo analysis set03130
Pk/qtc analysis set7000
Completed593030
Not completed1322
Withdrew: Adverse event411
Withdrew: Withdrawal by subject411
Withdrew: Classified as 'other'500

Outcome measures

PrimaryThe Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (ΔΔQTc) on Day 14.

Change from baseline in Cardiac Repolarization (QTc Interval) at Day 14 (Tizanidine 24 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.

Time frame:
Baseline and Day 14
Reported as:
Least squares mean · milliseconds (msec)
The Primary Endpoint Will be the Baseline-adjusted, Placebo-corrected Effect on QTc (ΔΔQTc) on Day 14.
milliseconds (msec)Tizanidine 24 mgTizanidine Placebo 24 mgTizanidine 24 mg Placebo-corrected
Timepoint (Hour) 0-4.3 (-6.3 to -2.3)-0.5 (-2.5 to 1.4)-3.7 (-6.6 to -0.9)
0.5-2.0 (-4.0 to 0.1)1.2 (-0.8 to 3.2)-3.2 (-6.0 to -0.3)
1-4.0 (-6.0 to -2.0)2.6 (0.6 to 4.5)-6.6 (-9.4 to -3.8)
1.5-4.7 (-6.9 to -2.6)2.7 (0.6 to 4.8)-7.4 (-10.5 to -4.4)
2-3.6 (-5.6 to -1.6)2.9 (0.9 to 4.8)-6.4 (-9.2 to -3.6)
41.6 (-0.4 to 3.6)3.4 (1.4 to 5.4)-1.8 (-4.6 to 1.0)
8-2.4 (-4.1 to -0.7)3.1 (1.4 to 4.8)-5.5 (-7.9 to -3.1)
12-2.0 (-3.5 to -0.5)1.0 (-0.5 to 2.5)-3.0 (-5.1 to -0.8)
240.4 (-1.3 to 2.2)2.6 (0.9 to 4.4)-2.2 (-4.6 to 0.2)
SecondaryThe Baseline-adjusted, Placebo-corrected (ΔΔQTc) on QTc Method Not Selected as Primary Endpoint.

Change from baseline in Cardiac Repolarization (QTc Interval) at Day 5 (Tizanidine 8 mg). Moxifloxacin was not investigational drug, it was used to assess the sensitivity of the study.

Time frame:
Baseline and Day 5
Reported as:
Least squares mean · msec
The Baseline-adjusted, Placebo-corrected (ΔΔQTc) on QTc Method Not Selected as Primary Endpoint.
msecTizanidine 8 mgTizanidine Placebo 8 mgTizanidine 8 mg Placebo-corrected
Timepoint (Hour) 0-0.8 (-2.5 to 0.8)-0.9 (-2.7 to 0.8)0.1 (-2.3 to 2.5)
0.5-0.4 (-2.3 to 1.4)0.4 (-1.5 to 2.3)-0.8 (-3.5 to 1.8)
10.0 (-1.9 to 1.9)2.3 (0.3 to 4.3)-2.3 (-5.1 to 0.4)
1.51.1 (-0.7 to 2.9)1.3 (-0.6 to 3.1)-0.1 (-2.7 to 2.4)
2-0.4 (-2.0 to 1.3)0.4 (-1.3 to 2.1)-0.7 (-3.1 to 1.6)
42.6 (1.2 to 4.0)1.0 (-0.5 to 2.5)1.6 (-0.4 to 3.6)
8-1.5 (-3.1 to 0.0)0.6 (-1.0 to 2.3)-2.2 (-4.4 to 0.1)
12-0.1 (-1.6 to 1.4)0.7 (-0.9 to 2.3)-0.8 (-3.0 to 1.5)
24-0.5 (-2.0 to 1.0)1.4 (-0.1 to 3.0)-1.9 (-4.1 to 0.3)
SecondaryAssessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling

The relationship will be quantified using a linear mixed effects model with an intercept. Data from Day 5 and Day 14 were fitted into regression model to obtain a slope of change. The measure type 'Number' followed by (90% Confidence Interval) shown in results is the slope from the linear fit.

Time frame:
Day 5, Day 14
Reported as:
Number · msec per ng/mL
Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling
msec per ng/mLTizanidine
Assessing the Relationship Between Changes in the QTc Interval and Plasma Levels of Tizanidine Using Concentration-effect Modeling-0.1209 (-0.1894 to -0.0524)
SecondaryMaximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
Time frame:
0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
ng/mLDay 5 (Tizanidine 8 mg)Day 14 (Tizanidine 24 mg)
Maximum Plasma Concentration (Cmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.11.7 ± 43.927.4 ± 42.7
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
Time frame:
0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)
Reported as:
Median · hour
Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
hourDay 5 (Tizanidine 8 mg)Day 14 (Tizanidine 24 mg)
Time to Reach Maximum Plasma Concentration (Tmax) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.1.35 (0.600 to 4.10)2.10 (0.600 to 4.10)
SecondaryArea Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
Time frame:
0.5, 1, 1.5, 2, 4, 8, 12 & 24 hours post dose on Days 5 (8 mg) and 14 (24 mg)
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.
ng*hr/mLDay 5 (Tizanidine 8 mg)Day 14 (Tizanidine 24 mg)
Area Under the Plasma Concentration-time Curve During a Dosing Interval (AUCt) of Single Doses of 8 and 24 mg Tizanidine After Reaching Steady State.32.4 ± 65.1115 ± 52.8

Adverse events

Collected over Up to 23 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tizanidine—0/72 (0%)44/72 (61.1%)
Initial Placebo and Crossover to Moxifloxacin—0/32 (0%)16/32 (50%)
Initial Moxifloxacin and Crossover to Placebo—1/32 (3.1%)23/32 (71.9%)
Placebo and Moxifloxacin Groups Combined—1/64 (1.6%)39/64 (60.9%)
Most frequent serious events
Most frequent serious events
EventTizanidineInitial Placebo and Crossover to MoxifloxacinInitial Moxifloxacin and Crossover to PlaceboPlacebo and Moxifloxacin Groups Combined
Ectopic PregnancyPregnancy, puerperium and perinatal conditions0/720/321/321/64
Most frequent other events
Showing 10 of 18
Most frequent other events
EventTizanidineInitial Placebo and Crossover to MoxifloxacinInitial Moxifloxacin and Crossover to PlaceboPlacebo and Moxifloxacin Groups Combined
NERVOUS SYSTEM DISORDERSNervous system disorders32/728/328/3216/64
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONSGeneral disorders24/729/329/3218/64
GASTROINTESTINAL DISORDERSGastrointestinal disorders21/728/3210/3218/64
SOMNOLENCENervous system disorders20/724/324/328/64
DIZZINESSNervous system disorders17/722/324/326/64
SKIN AND SUBCUTANEOUS TISSUE DISORDERSSkin and subcutaneous tissue disorders8/724/327/3211/64
FATIGUEGeneral disorders13/721/321/322/64
HEADACHENervous system disorders10/725/323/328/64
NAUSEAGastrointestinal disorders9/724/325/329/64
DRY MOUTHGastrointestinal disorders10/720/323/323/64

Baseline characteristics

Safety Population

Age, Continuous
Age, Continuous(years)TizanidineInitial Placebo and Crossover to MoxifloxacinInitial Moxifloxacin and Crossover to PlaceboTotal
Mean33.4 ± 6.7534.1 ± 7.5135.3 ± 7.2134.0 ± 7.03
Sex: Female, Male
Sex: Female, Male(Participants)TizanidineInitial Placebo and Crossover to MoxifloxacinInitial Moxifloxacin and Crossover to PlaceboTotal
Female39171773
Male33151563
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TizanidineInitial Placebo and Crossover to MoxifloxacinInitial Moxifloxacin and Crossover to PlaceboTotal
Hispanic or Latino3061248
Not Hispanic or Latino42262088
Unknown or Not Reported0000
08

Study locations

1 site
  • Covance- Dallas
    Dallas, Texas 75247, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Feb 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2013
First posted
Apr 24, 2013
Start
Apr 2013
Primary completionActual
Feb 2014
CompletionActual
May 2014
Results first posted
Jun 1, 2015
Last update
Mar 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01839279
Responsible party
Sponsor
First posted
Apr 24, 2013
Start date
Apr 2013
Primary completion
Feb 2014
Completion
May 2014
Results posted
Jun 1, 2015
Last update
Mar 23, 2021

Study contacts

Mathews Adera, MD
study director · Acorda Therapeutics

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tizanidine

Start the discussion